Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celgene Corporation
Perrigo can continue claiming its store brand hypoallergenic infant formula saves customers more than 20% compared to leading name brands while providing similar nutrition to leading brands. But meeting AAP standard doesn’t measure up as equivalent to brands, industry self-regulation group says.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
The microbiome therapy won approval for preventing recurrence of Clostridioides difficile infections, but an analyst said the future could be in more targeted approaches.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Delinia, Inc.
- EngMab AG
- Gloucester Pharmaceuticals, Inc.
- Impact Biomedicines, Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- X-BODY, Inc.